ENOS antibody (AA 34-1153)
Quick Overview for ENOS antibody (AA 34-1153) (ABIN7601375)
Target
See all ENOS (NOS3) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 34-1153
-
Purpose
- Anti-eNOS/NOS3 Antibody
-
Cross-Reactivity (Details)
- No cross-reactivity with other proteins.
-
Characteristics
- Anti-eNOS/NOS3 Antibody (ABIN7601375). Tested in ELISA, Flow Cytometry, IF, ICC, WB applications. This antibody reacts with Human. This is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications.
-
Purification
- Immunogen affinity purified.
-
Immunogen
- E.coli-derived human eNOS/NOS3 recombinant protein (Position: P34-Q1153).
-
Isotype
- IgG
-
-
-
-
Application Notes
-
Western blot, 0.25-0.5 μg/mL, Human
Immunocytochemistry/Immunofluorescence, 5 μg/mL, Human
Flow Cytometry (Fixed), 1-3 μg/1x106 cells, Human
ELISA, 0.1-0.5 μg/mL, -
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL.
-
Concentration
- 500 μg/mL
-
Buffer
- Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
-
At -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freezing and thawing.
-
-
- ENOS (NOS3) (Nitric Oxide Synthase 3 (Endothelial Cell) (NOS3))
-
Alternative Name
- NOS3
-
Background
-
Synonyms: Nitric oxide synthase, endothelial, Constitutive NOS, Cnos, EC-NOS, Endothelial NOS, eNOS, NOS type III, NOSIII, NOS3
Tissue Specificity: Platelets, placenta, liver and kidney.
Background: NOS3(Nitric Oxide Synthase 3), also called ENOS, anitric oxide synthasethat generatesNOinblood vesselsand is involved with regulatingvascular toneby inhibitingsmooth musclecontraction and plateletaggregation. The NOS3 gene is mapped on 7q36.1. Variations in this gene are associated with susceptibility tocoronary spasm. Fulton et al.(1999) concluded the eNOS is an AKT substrate linking signal transduction by AKT to the release of the gaseous second messenger nitric oxide. AKT mediates the activation of eNOS, leading to increased nitric oxide production. Inhibition of the PI3K AKT pathway or mutation of the AKT site on eNOS protein at serine-1177 attenuated the serine phosphorylation and prevented the activation of eNOS. RT-PCR analysis showed that expression ofNOS3in human umbilical vein endothelial cells (HUVECs) and human aortic vascular smooth muscle cells (HAOVSMCs) was inversely proportional to that of NOS3AS.
-
Molecular Weight
- 140 kDa
-
Gene ID
- 4846
-
UniProt
- P29474
-
Pathways
- ACE Inhibitor Pathway, Regulation of Systemic Arterial Blood Pressure by Hormones, Cellular Response to Molecule of Bacterial Origin, Myometrial Relaxation and Contraction, Signaling Events mediated by VEGFR1 and VEGFR2, Thromboxane A2 Receptor Signaling, VEGFR1 Specific Signals, VEGF Signaling
Target
-